recent
epidem
sar
occur
beij
anhui
china
april
origin
laboratori
contamin
updat
see
inform
sinc
new
case
sar
report
possibl
continu
global
vigil
surveil
laboratori
biosafeti
practic
well
euthan
quarantin
anim
may
expos
sarscov
although
outbreak
sar
seem
sar
still
safeti
concern
possibl
reintroduct
slcov
human
risk
escap
sarscov
laboratori
infect
sarscov
trigger
seri
humor
cellular
immun
respons
specif
antibodi
sarscov
immunoglobulin
g
igg
igm
detect
approxim
week
postinfect
reach
peak
day
postinfect
remain
high
level
day
postinfect
ref
high
titr
neutral
antibodi
sarscovspecif
cytotox
lymphocyt
respons
detect
patient
recov
sar
level
respons
correl
well
diseas
outcom
suggest
humor
cellular
immun
respons
crucial
clearanc
infect
sarscov
process
enabl
live
organ
cope
environment
stress
pressur
surviv
new
host
exampl
posit
select
pressur
civet
sarscov
evolv
subsequ
adapt
human
host
neutral
antibodi
andor
tcell
immun
respons
rais
directli
sever
sarscov
protein
mainli
target
protein
suggest
proteininduc
specif
immun
respons
play
import
part
fight
sarscov
infect
sarscov
protein
also
key
role
abil
sarscov
overcom
speci
barrier
adapt
evolut
protein
contribut
animaltohuman
transmiss
sarscov
protein
sarscov
involv
receptor
recognit
well
viru
attach
entri
repres
one
import
target
develop
sar
vaccin
therapeut
spike
sarscov
compos
trimer
protein
belong
group
class
viral
fusion
glycoprotein
also
includ
hiv
glycoprotein
env
influenza
haemagglutinin
ha
paramyxoviru
f
ebola
viru
glycoprotein
sarscov
protein
encod
surfac
glycoprotein
precursor
predict
amino
acid
length
amino
terminu
protein
predict
outsid
cell
surfac
viru
particl
predict
protein
consist
signal
peptid
amino
acid
locat
n
terminu
extracellular
domain
amino
acid
transmembran
domain
amino
acid
intracellular
domain
amino
acid
fig
similarli
coronavirus
protein
sarscov
cleav
subunit
proteas
trypsin
factor
xa
cathepsin
l
trypsin
cleavag
site
occur
ref
wherea
cathepsin
l
cleavag
map
protein
cathepsin
l
cleav
protein
sarscov
upstream
rather
adjac
fusion
peptid
cleavag
requir
activ
membran
fusion
domain
protein
follow
entri
target
cell
angiotensinconvert
enzym
identifi
receptor
sarscov
fragment
locat
subunit
span
amino
acid
minim
receptorbind
domain
rbd
crystallograph
studi
shown
structur
rbd
complex
receptor
ref
interact
rbd
receptor
rbd
present
concav
surfac
n
terminu
receptor
peptidas
amino
acid
anchor
entir
receptorbind
loop
rbd
core
fig
loop
amino
acid
rbd
make
complet
contact
receptor
refer
receptorbind
motif
rbm
fig
rbm
region
tyrosin
rich
among
residu
rbm
direct
contact
six
tyrosin
repres
hydroxyl
group
hydrophob
ring
rbd
region
also
contain
multipl
cystein
residu
link
disulphid
bond
fig
two
residu
particular
posit
determin
sar
diseas
progress
sarscov
tropism
host
rang
residu
chang
two
posit
might
therefor
enhanc
animaltohuman
humantohuman
transmiss
human
anim
sarscov
depend
cell
entri
anim
sarscov
could
evolv
infect
human
seri
transmiss
event
anim
human
exampl
chimer
recombin
sarscov
bear
protein
civet
sarscov
adapt
human
airway
epitheli
cell
display
enhanc
affin
human
ref
chang
residu
rbd
civet
sarscov
protein
respons
bind
peptidas
domain
result
enhanc
human
affin
sarscov
anim
includ
civet
mice
rat
facilit
effici
crossspeci
infect
howev
slcov
bat
infect
cell
suggest
unlik
sarscov
human
civet
slcov
bat
use
cellular
receptor
thu
slcov
bat
might
precursor
anim
sarscov
may
act
intermedi
animaltohuman
transmiss
function
sarscov
protein
sarscov
protein
pivot
role
viral
infect
pathogenesi
recogn
bind
host
receptor
subsequ
conform
chang
facilit
fusion
viral
envelop
host
cell
membran
receptor
bind
rbd
respons
viru
bind
host
cell
receptor
sarscovpermiss
vero
cell
effici
bind
solubl
form
block
associ
vero
cell
addit
sarscov
replic
effici
cell
antibodi
block
viru
entri
replic
vero
cell
show
function
receptor
sarscov
total
residu
keep
contact
amino
acid
rbd
sarscov
protein
rbd
import
complex
format
rbd
import
highaffin
associ
protein
ref
point
mutat
rbd
disrupt
antigen
structur
bind
activ
rbd
ref
sever
acut
respiratori
syndromecoronaviru
sarscov
spread
primarili
droplet
respiratori
secret
close
persontoperson
contact
viru
enter
bodi
bind
primari
target
cell
express
abund
viru
receptor
angiotensinconvert
enzym
includ
pneumocyt
enterocyt
respiratori
system
viru
enter
replic
cell
matur
virion
releas
infect
new
target
cell
fig
sarscov
also
infect
mucos
cell
intestin
tubular
epitheli
cell
kidney
epitheli
cell
renal
tubul
cerebr
neuron
immun
cell
infecti
viral
particl
patient
sar
excret
respiratori
secret
stool
urin
sweat
sarscov
infect
damag
lung
tissu
owe
elev
level
product
activ
proinflammatori
chemokin
cytokin
result
atyp
pneumonia
rapid
respiratori
deterior
failur
sarscov
also
bind
host
cell
altern
receptor
dcsign
dendrit
cellspecif
intercellular
adhes
nonintegrin
andor
lsign
liverlymph
nodesign
seven
asparaginelink
glycosyl
site
protein
includ
residu
posit
crucial
dcsignor
lsignmedi
viru
entri
residu
differ
domain
locat
amino
acid
ref
would
suggest
protein
also
use
dcsign
lsign
receptor
independ
howev
actual
function
dcsign
lsign
need
verifi
fusion
process
mediat
protein
sarscov
similar
mediat
class
viral
fusion
protein
virus
murin
hepat
viru
mhv
may
occur
acid
environ
endosom
rather
cell
surfac
contain
heptad
repeat
domain
play
import
part
sarscov
fusion
target
cell
bind
rbd
receptor
trigger
conform
chang
prefus
form
postfus
form
result
insert
put
fusion
peptid
amino
acid
target
cell
membran
associ
protein
first
bind
cellular
receptor
angiotensinconvert
enzym
complex
transloc
endosom
protein
cleav
endosom
acid
proteas
cathepsin
l
activ
fusion
activ
viral
genom
releas
translat
viral
replicas
polyprotein
cleav
small
product
viral
proteinas
subgenom
negativestrand
templat
synthes
discontinu
transcript
plusstrand
genom
serv
templat
mrna
synthesi
fulllength
negativestrand
templat
made
templat
genom
rna
viral
nucleocapsid
assembl
genom
rna
n
protein
cytoplasm
follow
bud
lumen
ergic
endoplasm
reticulum
er
golgi
intermedi
compart
virion
releas
cell
exocytosi
synthet
viru
bear
sarscov
protein
contain
envdefect
luciferaseexpress
genom
retroviru
exampl
hiv
infect
replic
cell
express
receptor
sarscov
domain
form
sixhelix
bundl
fusion
core
structur
bring
viral
envelop
target
cell
membran
close
proxim
fusion
crystal
structur
sarscov
fusion
core
describ
detail
ref
fig
similarli
protein
mhv
sarscov
protein
longer
region
region
sixhelix
bundl
fusion
core
rodshap
structur
length
diamet
three
helic
form
parallel
trimer
coiledcoil
surround
three
helic
obliqu
antiparallel
manner
fig
synthet
peptid
deriv
region
could
interact
peptid
form
stabl
sixhelix
bundl
inhibit
sarscov
infect
dosedepend
manner
consequ
region
domain
expect
particip
viral
fusion
entri
process
serv
attract
target
develop
antisarscov
therapeut
vaccin
vaccin
base
sarscov
protein
role
protein
receptor
bind
membran
fusion
indic
vaccin
base
protein
could
induc
antibodi
block
viru
bind
fusion
neutral
viru
infect
among
structur
protein
sarscov
protein
main
antigen
compon
respons
induc
host
immun
respons
neutral
antibodi
andor
protect
immun
viru
infect
protein
therefor
select
import
target
vaccin
antivir
develop
comparison
approach
provid
tabl
report
antibodi
rais
amino
acid
neutral
infect
sarscov
strain
exampl
vero
cell
vaccin
african
green
monkey
attenu
parainfluenza
viru
encod
fulllength
protein
sarscov
urbani
strain
result
product
proteinspecif
neutral
antibodi
protect
vaccin
monkey
subsequ
homolog
sarscov
challeng
suggest
immun
protein
sarscov
highli
effect
prevent
sar
sever
vaccin
base
fulllength
protein
sarscov
report
yang
et
al
show
dna
vaccin
encod
fulllength
protein
sarscov
urbani
strain
could
induc
tcell
neutralizingantibodi
respons
well
protect
immun
mous
model
group
also
shown
vaccin
mice
monkey
highli
attenu
modifi
vaccinia
viru
ankara
mva
encod
fulllength
protein
sarscov
urbani
strain
strain
elicit
sspecif
neutral
antibodi
protect
immun
evidenc
decreas
viru
titr
respiratori
tract
anim
homolog
sarscov
challeng
passiv
transfer
murin
serum
naiv
mice
also
protect
mice
challeng
homolog
sarscov
addit
vaccin
mice
hamster
fulllength
protein
trimer
protect
anim
infect
homolog
sarscov
strain
furthermor
recombin
baculovirusexpress
fulllength
protein
urbani
strain
trimer
could
induc
suffici
neutral
antibodi
human
palm
civet
sar
pseudovirus
bore
protein
homolog
heterolog
sarscov
variant
exampl
strain
vaccin
mice
report
suggest
fulllength
protein
highli
immunogen
induc
protect
sarscov
challeng
neutral
antibodi
alon
may
abl
suppress
viru
prolifer
justifi
rational
vaccin
develop
base
protein
although
fulllength
proteinbas
sar
vaccin
induc
neutral
antibodi
respons
sarscov
infect
may
also
induc
harm
immun
respons
caus
liver
damag
vaccin
anim
enhanc
infect
challeng
b
crystal
structur
rbd
complex
receptor
rbd
core
structur
cyan
loop
rbm
red
interact
receptor
angiotensinconvert
enzym
green
fivestrand
antiparallel
connect
three
short
constitut
core
wherea
twostrand
form
loop
n
c
repres
amino
carboxyl
termini
rbd
respect
c
rbd
tyrosin
magenta
cystein
yellow
residu
distribut
asterisk
repres
six
tyrosin
rbd
two
disulphid
bond
shown
link
shown
rbd
protein
coronavirus
mhv
contain
major
antigen
determin
induc
neutral
antibodi
discov
recombin
rbd
rrbd
antigen
sarscov
highli
reactiv
neutral
antibodi
sar
pseudovirus
bear
protein
sarscov
strain
antisera
mice
rabbit
immun
inactiv
sarscov
rbd
strongli
react
antisera
patient
sar
convalesc
phase
deplet
rbdspecif
antibodi
patient
sar
result
signific
elimin
neu
raliz
activ
chen
et
al
also
shown
neutral
antibodi
antisera
mice
rabbit
monkey
induc
liveattenu
mva
viru
express
fulllength
protein
could
absorb
remov
rrbd
use
fusion
protein
contain
rbd
link
human
fc
fragment
design
rbdfc
immunogen
success
induc
highli
potent
neutral
antibodi
sarscov
strain
immun
rabbit
neutral
titr
greater
ref
note
efficaci
vaccin
candid
mainli
test
youngmous
primat
anim
model
model
usual
less
robust
provid
viru
replic
lack
clinic
symptom
diseas
necessari
therefor
develop
morerobust
anim
model
human
diseas
evalu
vaccin
efficaci
baric
colleagu
recent
report
sever
lethal
sarscov
challeng
model
balbc
mice
recapitul
agerel
sar
diseas
use
recombin
sarscov
bore
protein
earli
human
zoonot
strain
respect
also
develop
anoth
pathogen
model
young
mice
passag
urbani
isol
balbc
mice
result
lethal
viru
replic
high
titr
lung
mice
caus
clinic
diseas
sar
report
list
exampl
use
senesc
mous
model
vaccin
evalu
one
candid
vaccin
venezuelan
equin
enceph
viru
replicon
particl
express
urbani
sarscov
protein
partial
protect
age
mice
challeng
recombin
heterolog
sarscov
bore
epidem
zoonot
protein
provid
model
mimic
agerel
suscept
observ
elder
popul
anim
model
discuss
use
valuabl
tool
evalu
efficaci
sar
vaccin
shown
rrbd
block
proteinmedi
entri
lentiviru
pseudotyp
cell
half
maxim
inhibitori
concentr
ic
less
nm
similarli
peptid
overlap
rbd
sequenc
amino
acid
block
interact
inhibit
sarscov
entri
vero
cell
ic
approxim
polypeptid
contain
two
rbdbind
motif
amino
acid
link
glycin
exhibit
high
potent
inhibitori
activ
sar
pseudoviru
infect
hela
cell
ic
nm
find
suggest
peptid
deriv
rbd
block
bind
could
develop
novel
therapeut
sarscov
infect
howev
vivo
inhibitori
activ
peptid
evalu
anim
model
consid
develop
cleavag
protein
trimer
import
event
infect
make
potenti
cleavag
site
domain
anoth
target
develop
antisarscov
agent
synthet
peptid
includ
amino
acid
amino
acid
close
connect
cleavag
site
exhibit
potent
inhibitori
activ
strain
sarscov
infect
fetal
rhesu
kidney
suggest
bind
peptid
protein
interfer
cleavag
inhibit
product
function
subunit
subsequ
fusion
viral
envelop
host
cell
membran
vivo
antivir
efficaci
peptid
test
anim
model
earli
jiang
et
al
wild
et
al
discov
highli
potent
antihiv
peptid
deriv
region
one
peptid
enfuvirtid
approv
us
food
drug
administr
treatment
patient
hiv
aid
especi
fail
respond
current
antiretrovir
drug
peptid
could
interact
viral
region
fusionintermedi
conform
block
sixhelix
bundl
format
result
inhibit
hiv
fusion
nanomolar
level
sarscov
protein
domain
also
contain
sequenc
anticip
peptid
deriv
region
sarscov
protein
domain
would
also
antivir
activ
sarscov
design
synthes
sever
peptid
overlap
sequenc
found
one
design
could
interact
peptid
form
stabl
sixhelix
bundl
inhibit
infect
sarscov
whu
strain
vero
cell
ic
approxim
later
sever
research
group
also
identifi
antisarscov
peptid
domain
region
viral
fusion
inhibitori
activ
micromolar
level
nmr
studi
shown
prefus
intermedi
state
region
form
symmetr
coiledcoil
trimer
observ
class
viral
fusion
protein
poor
antivir
activ
antisarscov
peptid
compar
antihiv
peptid
could
attribut
tendenc
sarscov
protein
region
form
trimer
coiledcoil
replac
key
residu
peptid
reduc
abil
form
trimer
increas
affin
bind
region
form
sixhelix
bundl
could
lead
improv
antivir
efficaci
peptid
antivir
drug
sar
emerg
infecti
diseas
short
incub
period
could
advantag
antihiv
drug
enfuvirtid
enfuvirtid
must
inject
twice
per
day
patient
lifetim
result
intoler
injectionsit
reaction
high
cost
patient
wherea
inject
peptid
drug
sarscov
earli
stage
acut
phase
could
enough
save
patient
live
one
disadvantag
use
peptid
inhibitor
potenti
select
escap
mutant
alter
hostrang
phenotyp
mab
target
protein
neutral
mous
mab
use
rrbd
inactiv
sarscov
immunogen
success
gener
panel
highli
potent
neutral
mous
monoclon
antibodi
mab
could
block
receptor
bind
crossneutr
infect
pseudovirus
bore
protein
repres
human
sar
cov
strain
caus
outbreak
palm
civet
sarscov
mous
mab
target
fragment
sarscov
protein
exampl
amino
acid
could
also
effect
inhibit
sarscov
infect
neutral
mous
mab
administ
patient
sar
earli
urgent
treatment
sarscov
infect
repeatedli
use
owe
risk
humanantimous
antibodi
respons
respons
could
rapidli
clear
murin
antibodi
blood
thu
prevent
mous
antibodi
produc
desir
therapeut
effect
caus
patient
allerg
reaction
antibodi
trimer
protein
potenti
mediat
entri
b
cell
vitro
therebi
caus
antibodydepend
enhanc
activ
cathepsin
l
proteas
could
develop
therapeut
inhibit
sarscov
infect
vivo
antivir
activ
test
anim
model
sever
compound
small
molecul
target
protein
report
exampl
amiodaron
block
vitro
spread
sarscov
inhibit
viru
infect
postendosom
level
yi
et
al
identifi
two
small
molecul
tetraogalloylbetadglucos
tgg
luteolin
inhibitori
activ
block
sarscov
sar
pseudoviru
entri
vero
cell
kao
et
al
identifi
small
molecul
target
viral
entri
one
exhibit
potent
inhibitori
activ
sar
pseudoviru
entri
cell
report
suggest
small
molecul
discuss
function
effect
antivir
inhibitor
proteinmedi
viral
entri
howev
studi
need
determin
vivo
efficaci
antivir
agent
anim
model
select
optim
formul
deliv
effect
concentr
drug
target
tissu
gene
target
small
interf
rna
rna
interfer
induc
small
interf
rna
sirna
success
use
recent
specif
effici
method
silenc
specif
viral
gene
interrupt
protein
synthesi
suppress
viru
replic
demonstr
sirna
direct
sequenc
sarscov
inhibit
sarscov
replic
virusinfect
vero
cell
sever
research
group
report
sspecif
sirna
could
reduc
protein
express
block
mrna
accumul
reduc
number
copi
viral
genom
cell
indic
gene
express
sarscovinfect
cell
effect
silenc
sspecif
sirna
vivo
studi
use
rhesu
macaqu
model
indic
sirna
duplex
target
protein
sarscov
could
suppress
sarslik
symptom
inhibit
viru
replic
monkey
respiratori
tract
protect
lung
acut
damag
find
discuss
reveal
function
sirna
inhibit
sarscov
infect
replic
andor
interrupt
gene
express
rais
hope
develop
effect
novel
antivir
agent
sarscov
summari
protein
sarscov
possess
uniqu
featur
differ
type
glycoprotein
mani
class
fusion
protein
hiv
env
influenza
ha
mhv
posttransl
cleav
nproxim
region
fusion
peptid
specif
proteas
surfac
transmembran
subunit
contrast
cleavag
sarscov
protein
may
occur
far
upstream
predict
fusion
peptid
fig
unlik
protein
coronavirus
cleav
furinlik
proteas
protein
sarscov
cleav
cathepsin
l
posit
trypsin
contrast
entranc
mechan
hiv
sarscov
enter
cell
acid
environ
endosom
nevertheless
sarscov
also
enter
target
cell
surfac
mediat
proteas
cell
surfac
nonendosomaldepend
pathway
interact
sarscov
protein
essenti
sarscov
entri
natur
evolut
epidem
sarscov
strain
probabl
occur
long
period
repeat
transmiss
virus
anim
human
human
anim
result
mutat
sarscov
protein
human
anim
sarscov
could
enter
cell
bore
human
anim
understand
tropism
viru
mechan
sarscov
protein
receptor
bind
entri
therefor
import
develop
antisarscov
therapeut
vaccin
major
compon
develop
vaccin
sar
protein
especi
rbd
shown
induc
highli
potent
neutral
antibodi
block
viru
bind
membran
fusion
andor
protect
immun
viru
infect
owe
absenc
human
sar
case
recent
year
futur
sar
epidem
probabl
origin
zoonot
transmiss
sar
vaccin
therefor
protect
human
sarscov
strain
includ
earli
middl
late
phase
epidem
also
zoonot
origin
although
current
vaccin
candid
effect
neutral
sarscov
younganim
replic
model
without
clinic
symptom
may
protect
elderli
popul
sarscov
infect
thu
essenti
test
vaccin
candid
robust
lethalchalleng
model
use
age
anim
futur
vaccin
effect
protect
young
elderli
popul
infect
either
human
anim
sarscov
strain
may
caus
futur
sar
epidem
peptid
nonpeptid
small
molecul
target
function
domain
sarscov
protein
particularli
rbd
subunit
region
subunit
mainli
viru
entri
inhibitor
develop
antisarscov
therapeut
develop
molecul
effect
safe
antivir
drug
treatment
sar
urgent
task
improv
potenc
mous
human
mab
target
protein
sarscov
shown
potent
inhibit
andor
neutral
homolog
heterolog
sarscov
isol
develop
immunotherapeut
passiv
immun
agent
therapi
prophylaxi
sarscov
infect
futur
studi
need
test
vivo
efficaci
antivir
agent
anim
model
overal
feasibl
use
peptid
small
molecul
antisar
therapeut
partial
limit
low
antivir
potenc
furthermor
possibl
enhanc
viral
entri
might
restrict
mab
immunotherapeut
longterm
use
like
howev
proteinbas
vaccin
bear
fruit
near
futur
proven
induc
longterm
potent
neutral
antibodi
andor
protect
immun
sarscov
vivo
efficaci
vaccin
candid
elderli
lethalchalleng
model
protect
zoonot
viru
infect
determin
clinic
studi
initi
take
factor
full
consider
combin
differ
strategi
multipl
vaccin
antivir
therapeut
may
need
induc
broad
cross
protect
variou
viru
strain
especi
isol
mutat
quickli
earli
clinic
studi
base
strategi
carri
difficult
push
clinic
trial
candid
vaccin
therapeut
forward
owe
lack
sarscovinfect
subject
insuffici
financi
support
thu
big
pharmaceut
compani
interest
develop
sar
vaccin
therapeut
concern
profit
howev
studi
sar
provid
import
inform
design
novel
strategi
prophylaxi
therapi
newli
emerg
infect
caus
envelop
virus
class
fusion
protein
